three years of half-life threads, summarised so you do not have to read them
three years of half-life threads, summarised so you do not have to read them, which sounds obvious until you try to state the evidence for it.
Went looking for human data on a mechanism everybody here asserts. Found preclinical work and one small study. That was clarifying.
The mental model, in four steps, that makes the rest of this site legible.
One: gut hormones amplify the insulin response to food. Two: agonists at those receptors act peripherally on insulin secretion and gastric emptying, and centrally on appetite. Three: structural modification gives them a long half-life, so exposure is smooth and weekly. Four: tolerance develops to some effects and not to others.
From those four, most of what the experience boards report falls out: why the side effects cluster early, why they settle at a stable dose, why appetite reduction persists, and why the scale and the appetite move on different clocks.
Asked a question here that I thought was stupid and got three papers back. Best thread I have been in on this site.
Screenshot none of this. Read the whole thread, including the parts where I am told I am wrong.
best — the order this archive was captured in
Receptor expression in a tissue is necessary but not sufficient for an effect. You also need the agonist to reach it at relevant exposure, and that is where a lot of confident mechanism talk falls down.
Push back: a receptor being expressed in a tissue does not tell you the agonist reaches it at therapeutic exposure.
Do you have the paper, or a summary of it?
Yes. The central component is the one that explains the reports on this site better than gastric emptying does.
The incretin effect is the observation that oral glucose provokes a larger insulin response than intravenous glucose at matched glycaemia, and the difference is mediated by gut hormones. That is the foundation the whole class sits on.
GIP receptor biology is genuinely unsettled — there is a live argument about agonism versus antagonism at the receptor — and the clinical results are robust regardless, which is an uncomfortable and interesting position.